News

Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial (1) presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life.

The International Association for the Study of Lung Cancer (IASLC) seeks a Vendor to produce a daily “newspaper” during each day of its annual world conference.

IASLC Newsletter - March 2018

Immunotherapy has recently emerged as a new treatment modality in lung cancer, and reactivating immune responses that are silenced by immune checkpoints is an idea that has recently gained a lot of interest.

The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi.

Pages